 | ARCA biopharma
Business: Drug discovery based on pharmacogenomics of heart disease.
Update: IPO (NASDAQ:ABIO) January, 2009.
Co-investors: Atlas Ventures; Skyline Ventures; InterWest Partners |
| | |
| | |
 | Array Biopharma
Business: Array is a discovery research organization that sells chemicals and services to the pharmaceutical industry.
Update: IPO (NASDAQ:ARRY) November, 2000.
Co-investors: Falcon Technology Ventures; Frazier & Co.; ARCH Ventures; Advent International; Mitsui & Co. USA |
| | |
| | |
 | Barofold
Business: Barofold will commercialize patented technology that will dramatically improve the cost of purity and manufacturing protein molecules.
Co-investors: HBM Partners
|
| | |
| | |
 | BiOptix
Business: BiOptix is an analytical instrument company developing a novel interferometer to enable label free detection of biological samples. |
| | |
| | |
 | Dharmacon
Business: Leading supplier worldwide of synthetic RNA
Update: Sold to Fisher Scientific (NYSE:FSH) March, 2004.
Co-investors: Telegraph Hill Partners |
| | |
| | |
 | Entelos, Inc.
Business: Entelos software and services offer decision-support and disease knowledge management for biopharmaceutical researchers. Update: IPO on London AIM April, 2006.
Co-investors: Abingworth Management; Charles River Partners; St. Paul Venture Partners |
| | |
| | |
 | Genomica
Business: Genomica's database software, Discovery Manager, allows researchers to organize and analyze genetic sequences for drug discovery.
Update: IPO (NASDAQ:GNOM); Sold to Exelixis November, 2001.
Co-investors: Falcon Technology Partners; ARCH Venture Partners; INVESCO Trust Company; The Kaufmann Fund |
| | |
| | |
 | Millennium Pharmacy Systems, Inc.
Business: Millennium Pharmacy Systems offers technology-enabled institutional pharmacy services.
Co-investors: CHL Medical Partners; Essex Woodland |
| | |
| | |
 | Hiberna Corporation
Business: Drug development based on novel model organisms that exhibit profound biology.
Co-investors: Peierls Foundation |
| | |
| | |
 | MiRagen Therapeutics
Business: MicroRNA applications in cardiovascular disease.
Co-investors: Atlas Venture |
| | |
